Piper Sandler raises Oscar Health stock price target on ACA growth
Piper Sandler raised its price target for Oscar Health (OSCR) to $48, citing ACA growth and a 12x multiple on 2030 earnings. The stock has surged 139% in six months, with analysts predicting profitability this year. Oscar Health reported strong Q2 2026 results, exceeding earnings and revenue expectations, and raised its 2026 guidance.
How this was made
The 30-second read
Why it matters
The earnings beat and target raise could drive short-term buying pressure.
Market read
Oscar Health's earnings beat and upgraded targets provide a fresh catalyst for traders.
What to watch
Potential regulatory changes to ACA could affect future earnings.
Background
Oscar Health reported stronger-than-expected Q2 2026 results and received an analyst price target increase.
Ticker impact
Piper Sandler raised OSCR price target to $48 and reported Q2 2026 earnings beat with $1.10 EPS and higher revenue.
Potential rally toward the new $48 target.
Target raise and earnings beat provide a clear catalyst for price appreciation.
Market effects
Positive signal for health insurance and ACA-related stocks.
U.S. market focus on health insurers.
Limited to U.S. healthcare sector.
Counterpoint
Target may be overly optimistic if ACA enrollment growth slows.
Key entities
- AnalystPiper Sandler
Raised price target to $48, Overweight rating.
- AnalystBofA Securities
Raised price target to $30, Underperform rating.
